Synthetic heart graft patient reaches milestone:
This article was originally published in Clinica
Executive Summary
CardioTech International says that the first recipient of its investigational synthetic coronary artery bypass graft, CardioPass, has reached the one-year mark. The female patient, who had been considered a "no option" patient because she had no usable mammary artery, received the implant in Brazil in August 2003. She is currently leading a normal life, is asymptomatic and has no cardiac pain, said the Wilmington, Massachusetts firm. Her blood pressure and EKG are also both normal. In addition, two further patients who received the implant last year are also leading normal lives. CardioPass is designed to obviate the need for vessel harvesting surgery. CardioTech estimates the annual worldwide market for the synthetic graft will be in excess of $1bn.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.